Therefore, several inhibitors of p38 MAPK that exhibit different potency and kinase selectivity, all of them most potently blocking p38α versus other p38 isoforms (p38β, p38γ, p38δ) have been administered during the acute phase in experimental models of cerebral ischemia, and all of them have provided robust neuroprotection [30, 33–37]. The gene discussed is MAPK14; the disease is Cerebral ischemia.